Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular PanelGlobeNewsWire • 09/22/20
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future PlansGlobeNewsWire • 09/04/20
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/17/20
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20GlobeNewsWire • 07/22/20
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/20/20
Precipio Completes the Transaction with Poplar Healthcare’s Oncometrix Hematopathology DivisionGlobeNewsWire • 03/16/20
Precipio achieves impressive initial results of Artificial Intelligence Decision-Support ToolGlobeNewsWire • 02/26/20
Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnershipGlobeNewsWire • 02/18/20
Precipio's (PRPO) CEO Ilan Danieli on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/14/19
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™GlobeNewsWire • 09/30/19